| Literature DB >> 21192850 |
Emily E Sickbert-Bennett1, David J Weber, Charles Poole, Pia D M MacDonald, Jean-Marie Maillard.
Abstract
Despite widespread use of communicable disease surveillance data to inform public health intervention and control measures, the reporting completeness of the notifiable disease surveillance system remains incompletely assessed. Therefore, we conducted a comprehensive study of reporting completeness with an analysis of 53 diseases reported by 8 health care systems across North Carolina, USA, during 1995-1997 and 2000-2006. All patients who were assigned an International Classification of Diseases, 9th Revision, Clinical Modification, diagnosis code for a state-required reportable communicable disease were matched to surveillance records. We used logistic regression techniques to estimate reporting completeness by disease, year, and health care system. The completeness of reporting varied among the health care systems from 2% to 30% and improved over time. Disease-specific reporting completeness proportions ranged from 0% to 82%, but were generally low even for diseases with great public health importance and opportunity for interventions.Entities:
Mesh:
Year: 2011 PMID: 21192850 PMCID: PMC3204630 DOI: 10.3201/eid1701.100660
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
. Disease-specific reporting completeness proportions in North Carolina, USA, 2000–2006*
| Communicable disease | No. reported to NC DHHS | No. identified by ICD-9-CM codes | Unadjusted RCP, % (95% CI) | Semi-Bayesian adjusted RCP, % (95% UI) |
|---|---|---|---|---|
| Anthrax | 0 | 14 | 0.01 (0.00–100.00) | 0.00 (0.00–100.00) |
| Arboviral encephalitis | 0 | 18 | 0.00 (0.00–100.00) | 8.67 (0.80–52.77) |
| Botulism | 0 | 4 | 0.02 (0.00–100.00) | 0.08 (0.00–100.00) |
| Brucellosis | 0 | 33 | 0.00 (0.00–100.00) | 23.02 (1.36–86.62) |
| Campylobacteriosis | 39 | 97 | 40.21 (30.94–50.22) | 39.96 (30.82–49.85) |
| Cholera | 0 | 6 | 0.01 (0.00–100.00) | 18.58 (2.24–69.41) |
| CJD/vCJD | 0 | 32 | 0.00 (0.00–100.00) | 0.87 (0.03–22.97) |
| Cryptosporidiosis | 10 | 84 | 11.90 (6.53–20.73) | 12.59 (7.07–21.42) |
| Cyclosporiasis | 0 | 3 | 0.03 (0.00–100.00) | 18.59 (2.25–69.42) |
| Dengue | 4 | 25 | 16.00 (6.14–35.69) | 14.48 (5.92–31.31) |
| Diphtheria | 0 | 5 | 0.02 (0.00–100.00) | 8.28 (0.82–49.70) |
| 1 | 3 | 33.33 (4.34–84.65) | 24.67 (5.82–63.45) | |
| Foodborne staphylococcal infection | 0 | 14 | 0.01 (0.00–100.00) | 74.74 (16.74–97.76) |
| Granulocytic ehrlichiosis | 0 | 67 | 0.00 (0.00–100.00) | 8.66 (0.80–52.74) |
| Hantavirus infection | 0 | 3 | 0.03 (0.00–100.00) | 10.10 (0.62–67.06) |
| Hemolytic uremic syndrome | 5 | 429 | 1.17 (0.49–2.77) | 2.20 (0.99–4.84) |
|
| 14 | 1,086 | 1.29 (0.76–2.16) | 1.45 (0.87–2.42) |
| Hepatitis A | 27 | 866 | 3.12 (2.15–4.51) | 3.34 (2.31–4.81) |
| Legionellosis | 24 | 98 | 24.49 (16.99–33.95) | 24.04 (16.72–33.27) |
| Leptospirosis | 0 | 33 | 0.00 (0.00–100.00) | 23.02 (1.36–86.62) |
| Listeriosis | 10 | 64 | 15.63 (8.62–26.67) | 16.14 (9.12–26.95) |
| Lyme disease | 8 | 790 | 1.01 (0.51–2.01) | 1.18 (0.60–2.30) |
| Malaria | 17 | 155 | 10.97 (6.93–16.94) | 10.71 (6.80–16.47) |
| Measles | 0 | 14 | 0.01 (0.00–100.00) | 15.98 (1.41–71.63) |
| Meningococcal disease | 38 | 179 | 21.23 (15.85–27.83) | 21.19 (15.85–27.73) |
| Monocytic ehrlichiosis | 1 | 4 | 25.00 (3.35–76.22) | 14.84 (3.12–48.52) |
| Mumps | 1 | 96 | 1.04 (0.15–7.02) | 1.07 (0.20–5.49) |
| Plague | 0 | 28 | 0.00 (0.00–100.00) | 0.00 (0.00–100.00) |
| Pneumococcal meningitis | 20 | 191 | 10.47 (6.86–15.67) | 10.61 (6.99–15.80) |
| Polio, paralytic | 0 | 32 | 0.00 (0.00–100.00) | 18.56 (2.24–69.38) |
| Psittacosis | 0 | 21 | 0.00 (0.00–100.00) | 17.45 (1.57–73.69) |
| Q fever | 3 | 14 | 21.43 (7.07–49.43) | 25.68 (9.14–54.28) |
| Rabies, human | 0 | 12 | 0.01 (0.00–100.00) | 59.69 (8.00–96.19) |
| Rocky Mountain spotted fever | 40 | 986 | 4.06 (2.99–5.48) | 4.19 (3.10–5.66) |
| Rubella | 0 | 39 | 0.00 (0.00–100.00) | 15.97 (1.41–71.61) |
| Rubella congenital syndrome | 0 | 10 | 0.01 (0.00–100.00) | 1.08 (0.07–15.32) |
| Salmonellosis | 263 | 594 | 44.28 (40.33–48.30) | 44.82 (40.87–48.83) |
| SARS (coronavirus infection) | 0 | 1 | 0.08 (0.00–100.00) | 5.71 (0.28–56.27) |
| Shigellosis | 38 | 213 | 17.84 (13.26–23.57) | 18.17 (13.56–23.93) |
| Smallpox | 0 | 9 | 0.01 (0.00–100.00) | 0.00 (0.00–100.00) |
| Streptococcal infection, group A | 8 | 111 | 7.21 (3.65–13.75) | 7.40 (3.80–13.92) |
| Tetanus | 1 | 20 | 5.00 (0.70–28.22) | 5.25 (1.09–21.78) |
| Toxic shock syndrome | 4 | 142 | 2.82 (1.06–7.26) | 3.22 (1.28–7.83) |
| Trichinosis | 0 | 23 | 0.00 (0.00–100.00) | 20.21 (1.82–77.58) |
| Tuberculosis | 100 | 1,439 | 6.95 (5.74–8.38) | 7.10 (5.87–8.55) |
| Tularemia | 0 | 6 | 0.01 (0.00–100.00) | 0.04 (0.00–100.00) |
| Typhoid, acute | 3 | 12 | 25.00 (8.28–55.18) | 21.57 (7.49–48.30) |
| Typhus, epidemic (louse-borne) | 0 | 2 | 0.04 (0.00–100.00) | 2.93 (0.12–42.63) |
| Vaccinia | 0 | 13 | 0.01 (0.00–100.00) | 8.27 (0.82–49.68) |
| 0 | 1 | 0.08 (0.00–100.00) | 81.58 (20.46–98.71) | |
| 0 | 2 | 0.04 (0.00–100.00) | 81.57 (20.45–98.71) | |
| Whooping cough (pertussis) | 11 | 54 | 20.37 (11.65–33.16) | 20.31 (11.78–32.72) |
| Yellow fever | 0 | 3 | 0.03 (0.00–100.00) | 8.69 (0.80–52.81) |
*NC DHHS, North Carolina Department of Health and Human Services; ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; RCP, reporting completeness proportions; CI, confidence interval; UI, uncertainty interval; CJD, Creutzfeldt-Jakob disease; vCJD, variant CJD; SARS, severe acute respiratory syndrome.
Figure 1Reporting completeness of communicable diseases in North Carolina, USA, by year, with 95% confidence intervals, 2000–2006.
Figure 2Reporting completeness of communicable diseases in North Carolina, USA, by health care system, 2000–2006. Error bars indicate 95% confidence intervals.